2-(4,5-二甲氧基-2-硝基苯基)乙胺 | 37852-39-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4,5-二甲氧基-2-硝基苯基)乙胺
• 英文名称: [2-(2-nitro-4,5-dimethoxyphenyl)ethyl]amine
• 英文别名: 2-(4,5-Dimethoxy-2-nitrophenyl)ethanamine
• CAS: 37852-39-4
• 化学式: C₁₀H₁₄N₂O₄
• mdl: MFCD01935139
• 分子量: 226.232
• InChiKey: XRCCQNXLMRHYBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  90.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  2-(4,5-二甲氧基-2-硝基苯基)乙胺 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 反应 72.0h， 以2.4 g的产率得到2-(2-Ammonioethyl)-4,5-dimethoxy-anilinium-dichlorid
  参考文献：
  名称：

  来自邻氨基苯甲醇和邻氨基苄胺的 3,1-苯并恶嗪和四氢喹唑啉 - 环化行为的半经验 MO 计算

  摘要：

  O-氨基苯甲醇 (4) 与醛和酮缩合得到 3,1-苯并恶嗪 20a/b 和 22a/b，而烯胺衍生物 24a-c 与 β-二酮形成。与等排邻氨基苄胺（1），杂环产物为四氢喹唑啉11a/b和14b，1,4-二胺如2和3反应生成开链化合物15、16b、18a和19。行为可以与用半经验 MNDO 方法计算的反应焓相关联。

  DOI：

  10.1002/ardp.19943270510
• 作为产物：
  描述：

  3,4-二甲氧基苯乙胺 在 硝酸 作用下， 以 水 为溶剂， 反应 3.0h， 以77%的产率得到2-(4,5-二甲氧基-2-硝基苯基)乙胺
  参考文献：
  名称：

  WOBE437 衍生的内源性大麻素摄取抑制剂的合成和生物学评价。

  摘要：

  WOBE437 ((2 E ,4 E )-N-(3,4-dimethoxyphenethyl)dodeca-2,4-dienamide, 1 ) 是一种天然产物衍生的高效内源性大麻素再摄取抑制剂。在这项研究中，我们合成了近 80 种1 的类似物，在十二二烯酰基结构域和二甲氧基苯乙基头部基团中进行了不同类型的修饰，并研究了它们对 U937 细胞摄取 anandamide 的影响。有趣的是，这些类似物都不是比 WOBE437 更有效的 anandamide 摄取抑制剂（1）。同时，许多 WOBE437 变体表现出低于 100 nM 的效力，对内源性大麻素降解酶脂肪酸酰胺水解酶的抑制具有高选择性；两种化合物实际上与1等效。有趣的是，在类似物之间观察到显着的活性差异，其中头部基团中的两个甲氧基取代基中的任何一个都被相同的更大的烷氧基取代。这里描述的一些化合物可能是开发具有更多类似药物特性的强效内源性大麻素摄取抑制剂的有趣出发点。

  DOI：

  10.1002/cmdc.202000153

文献信息

• HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY
  申请人：Grewal Gurmit

  公开号：US20100029643A1

  公开（公告）日：2010-02-04

  The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.

  该发明涉及化学式（I），（Ia）和（Ib）或其药学上可接受的盐的化合物，其具有Edg-1拮抗活性，因此在抗癌活性和人或动物体的治疗方法中有用。该发明还涉及制造上述化学化合物的过程，含有它们的制药组合物以及在制造用于在温血动物（如人）中产生抗癌效果的药物的制造中使用它们。
• Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates
  申请人：Northeastern University

  公开号：US11129790B2

  公开（公告）日：2021-09-28

  A method is provided for reversibly modifying a protein or peptide on its glutamine residue(s) by performing a reaction, such as a transglutaminase-catalyzed reaction, between the protein or peptide and an amine-containing reagent, whereby the reagent is linked through its amine function to a side chain of the glutamine residue. Subjecting the modified protein to an appropriate stimulus regenerates the protein or peptide in its original form.

  本发明提供了一种对蛋白质或肽的谷氨酰胺残基进行可逆修饰的方法，该方法是在蛋白质或肽与含胺试剂之间进行反应，如转谷氨酰胺酶催化反应，试剂通过其胺功能与谷氨酰胺残基的侧链相连。将修饰过的蛋白质置于适当的刺激下，蛋白质或肽就会以原来的形式再生。
• 42. Melanin and its precursors. Part VI. Further syntheses of 5 : 6-dihydroxyindole and its derivatives
  作者：John Harley-Mason

  DOI：10.1039/jr9530000200

  日期：——
• Synthesis of 4,5-dihydro-3H-1,3-benzodiazepines and 4,5-dihydro-1H-2,4-benzodiazepines
  作者：Herman R. Rodriguez、Barbara A. Zitko、George De Stevens

  DOI：10.1021/jo01266a042

  日期：1968.2
• In Vivo and in Vitro Studies on the Neurotoxic Potential of 6-Hydroxydopamine Analogs
  作者：Su Ma、Lorrie Lin、R. Raghavan、Pat Cohenour、Peter Y. T. Lin、Jennifer Bennett、Russell J. Lewis、Eric L. Enwall、Richard Kostrzewa

  DOI：10.1021/jm00020a024

  日期：1995.9

  In an attempt to determine which physical and biological properties could best be correlated with neurotoxic potential, seven analogs of 1-(2,4,5-trihydroxyphenyl)-2-aminoethane (1), better known as B-hydroxydopamine, were synthesized and compared to 1 in a variety of ways both in vivo and in vitro. The analogs, in combination with-the standard 1, include all eight of the 2,4,5-trisubstituted-phenyl derivatives of phenethylamine and alpha-methylphenethylamine in which the substitution is of the trihydroxy or aminodihydroxy form. Low (60 nmol) and high (300 nmol) intracerebroventricular doses of all analogs produced long-term (7 day) reduction of mouse whole brain norepinephrine (NE) and lesser depletions of dopamine (DA), and effects on serotonin were varied. The analog 1-(5-amino-2,4-dihydroxyphenyl)-2-aminopropane (8) was both more complete and more selective than the standard 1 in depleting NE. Using a histofluorometric glyoxylic acid method and Fink-Heimer silver degeneration stain, it was determined that overt neural degeneration was produced by 8. In vitro, the ease of oxidation of the eight analogs was found to be represented by a formal potential range of -130 to -212 mV vs SCE. However, there was no obvious relationship between ease of oxidation and the extent of monoamine depletion from mouse brain. Using kinetic analysis of synaptosomal accumulation of [H-3]NE and [H-3]DA, it was found that the standard 1 is more potent in its interaction with the DA uptake site (K-i = 12 +/- 0 mu M) than the NE uptake site (K-i = 51 +/- 1 mu M). A correlation analysis was used to determine that differences in NE and DA depletion by each analog could not be explained by differences in potency for in vitro uptake blockade. However, there was a correlation between the K-i for [H-3]NE uptake blockade and the EC(50) for synaptosomal release of preloaded [H-3]NE for the eight analogs (R(2) = 0.96; for log:log plot, R(2) = 0.54), indicating that the results for these two in vitro tests both reflect interaction with the same NE neuronal membrane transport site. A similar correlation between K-i and EC(50) was shown for all eight analogs using [H-3]DA (R(2) = 0.92; for log:log plot, R(2) = 0.52), indicating interaction with the same DA neuronal membrane transport site. These findings demonstrate that there is no single property that can account for selectivity of action and/or potency of catecholamine neurotoxins related to 6-hydroxydopamine.